2-methoxyestradiol inhibits the anaphase-promoting complex and protein translation in human breast cancer cells

2-methoxyestradiol (2ME2), an estradiol metabolite with antiproliferative and antiangiogenic activities, is in phase I/II clinical trials for breast cancer. 2ME2 inhibits microtubule polymerization and causes cells to arrest in G2-M. The purpose of this study was to further elucidate the molecular m...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2007-01, Vol.67 (2), p.702-708
Main Authors: BHATI, Rajendra, GÖKMEN-POLAR, Yesim, SLEDGE, George W, CHENG FAN, NAKSHATRI, Harikrishna, KETELSEN, David, BORCHERS, Christoph H, DIAL, Michael J, PATTERSON, Cam, KLAUBER-DEMORE, Nancy
Format: Article
Language:English
Subjects:
Anaphase-Promoting Complex-Cyclosome
Antineoplastic agents
Apoptosis - drug effects
Apoptosis - genetics
Biological and medical sciences
Breast Neoplasms - drug therapy
Breast Neoplasms - enzymology
Breast Neoplasms - genetics
Breast Neoplasms - pathology
Cell Cycle - drug effects
Cell Cycle - genetics
Cell Growth Processes - drug effects
Cell Line, Tumor
Estradiol - analogs & derivatives
Estradiol - pharmacology
Gynecology. Andrology. Obstetrics
Humans
Mammary gland diseases
Medical sciences
Mutation
Oligonucleotide Array Sequence Analysis
Pharmacology. Drug treatments
Protein Biosynthesis - drug effects
Tubulin - genetics
Tubulin - metabolism
Tubulin Modulators - pharmacology
Tumors
Ubiquitin-Protein Ligase Complexes - antagonists & inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:2-methoxyestradiol (2ME2), an estradiol metabolite with antiproliferative and antiangiogenic activities, is in phase I/II clinical trials for breast cancer. 2ME2 inhibits microtubule polymerization and causes cells to arrest in G2-M. The purpose of this study was to further elucidate the molecular mechanism of 2ME2. MDA-MB-435 breast cancer cells were treated with 2ME2 (2 micromol/L) or vehicle alone. RNA was extracted and genomic profiling was done using 22k Agilent microarrays. Expression Analysis Systematic Explorer was used to determine enrichment of Gene Ontology categories. Protein isolates were subjected to Western blot analysis. Protein synthesis was measured with a [35S]methionine pulse assay. An MDA-MB-435 cell line with two beta-tubulin mutations (2ME2R) was used to determine whether novel mechanisms were tubulin-dependent. Gene Ontology categories enriched include genes that regulate the mitotic spindle assembly checkpoint, apoptosis, and the cytosolic ribosome. The target of the mitotic spindle assembly checkpoint is the anaphase-promoting complex (APC). APC inhibition was confirmed by measuring protein levels of its targets securin and cyclin B1, which were increased in 2ME2-treated cells. Because gene expression in the cytosolic ribosome category was decreased, we evaluated whether 2ME2 decreases protein translation. This was confirmed with a pulse assay, which showed decreased isotope incorporation in 2ME2-treated cells, which was maintained in the tubulin-resistant 2ME2R cells. APC inhibition was not maintained in 2ME2R cells. 2ME2 induces tubulin-dependent cell cycle arrest through regulation of genes involved in the mitotic spindle assembly checkpoint, which results in inhibition of the APC and tubulin-independent inhibition of protein translation.
ISSN:0008-5472
1538-7445
DOI:10.1158/0008-5472.CAN-06-3406